Aclaris Therapeutics, Inc. (ACRS)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 1.8M | 3.3M | 1.3M | 2.0M |
| Gross Profit | -73K | 850K | -174K | 208K |
| Operating Income | -16.9M | -17.0M | -22.3M | -22.2M |
| Net Income | -15.4M | -14.6M | -19.8M | -19.8M |
| Diluted EPS | $-0.13 | $-0.12 | $-0.16 | $-0.15 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 29.8M | 31.2M | 18.7M | 7.8M |
| Gross Profit | 17.8M | 13.2M | 3.3M | 542K |
| Operating Income | -85.2M | -116.3M | -52.5M | -74.1M |
| Net Income | -86.9M | -88.5M | -132.1M | -64.9M |
| Diluted EPS | $-1.33 | $-1.27 | $-1.71 | $nan |